These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 32164483)

  • 1. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer.
    Dees S; Pontiggia L; Jasmin JF; Mercier I
    Cancer Biol Ther; 2020 Jun; 21(6):506-521. PubMed ID: 32164483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
    McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
    Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
    Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
    Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
    Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
    Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
    Bilir B; Kucuk O; Moreno CS
    J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway.
    Xie Q; Yang Z; Huang X; Zhang Z; Li J; Ju J; Zhang H; Ma J
    J Hematol Oncol; 2019 Jun; 12(1):60. PubMed ID: 31186039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
    Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3.
    Sharma U; Barwal TS; Khandelwal A; Malhotra A; Rana MK; Singh Rana AP; Imyanitov EN; Vasquez KM; Jain A
    Biochimie; 2021 Mar; 182():99-107. PubMed ID: 33429003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
    Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osthole inhibits triple negative breast cancer cells by suppressing STAT3.
    Dai X; Yin C; Zhang Y; Guo G; Zhao C; Wang O; Xiang Y; Zhang X; Liang G
    J Exp Clin Cancer Res; 2018 Dec; 37(1):322. PubMed ID: 30577812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 Targets
    Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
    Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
    He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
    Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
    Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
    Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.